Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

234

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 30, 2027

Conditions

Meniere´s Disease

Interventions

DRUG

Isosorbide oral solution

30 mL, TID

DRUG

Placebo

30 mL, TID

All Listed Sponsors

lead

Lunan Better Pharmaceutical Co., LTD.

INDUSTRY

NCT06765993 - Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease | Biotech Hunter | Biotech Hunter